Neurocrine recognized $54 million of those sales from May 18, the date the transaction closed. The company expects sequential quarterly growth as it exits 2026 and said it anticipates growth from the fourth quarter and beyond. Gano said Neurocrine expects discontinuation rates to eventually settle in a range of 25% to 30%, comparable with other orphan-drug products. The company expects roughly $150 million of acquisition-related costs, including $130 million recognized during the second quarter. About Neurocrine Biosciences (NASDAQ:NBIX)Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.